Bothell-based biotech company Seagen found success in a clinical trial testing a variety of cancer drugs. Roughly 1,000 participants joined the trial and some received a combination of Keytruda, a treatment from Merck & Co., and Seagen and Astellas’ drug Padcev.
The three companies stated that they achieved the two main goals of the trial: treated patients lived longer and did so without experiencing progressions in their diseases or symptoms. Earlier this year, the Keytruda-Padcev combination was approved on condition by the FDA due to its ability to drastically shrink tumors in clinical trials.